Both of the stocks highlighted in today’s article are clinical-stage biotechs, both are developing products to address the coronavirus pandemic (a vaccine in one case and a therapeutic in the other) – and both are “ultra-risky”. So what are the chances that either – or both – of these two ultra-risky stocks could make investors ultra wealthy? For more on these two stocks – one of which just made its market debut – CLICK HERE.
